Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
218. Back to Basics - Endometrial Cancer cover art

218. Back to Basics - Endometrial Cancer

218. Back to Basics - Endometrial Cancer

Listen for free

View show details
About this listen

This week we cover endometrial cancer. It is one of the clearest examples of molecular classification changing how we treat patients. PORTEC-3 randomised women with high-risk disease to pelvic radiotherapy with or without chemotherapy. Adding chemotherapy improved survival, and the benefit held at 10 years. The molecular analysis is where it gets interesting, but you'll have to tune in to find out why! RUBY then showed those same dMMR tumours respond to something else entirely. Adding dostarlimab to carboplatin-paclitaxel in advanced or recurrent disease improved overall survival. Should one molecular result now decide whether a patient gets chemotherapy, immunotherapy or both? In this episode, we unpack both trials and what they mean for practice.


Studies Discussed in Today's Episode

PORTEC-3

RUBY


For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com


Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/


Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.


Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content.

Hosted on Acast. See acast.com/privacy for more information.

adbl_web_anon_alc_button_suppression_t1
No reviews yet